Compare GSM & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSM | CTMX |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 723.2M | 716.9M |
| IPO Year | 2015 | 2015 |
| Metric | GSM | CTMX |
|---|---|---|
| Price | $3.86 | $2.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $12.25 |
| AVG Volume (30 Days) | 1.2M | ★ 3.2M |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.50% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $76,201,000.00 |
| Revenue This Year | $12.82 | N/A |
| Revenue Next Year | $20.75 | $1.24 |
| P/E Ratio | ★ N/A | $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.08 | $2.16 |
| 52 Week High | $5.66 | $8.21 |
| Indicator | GSM | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 41.45 | 38.82 |
| Support Level | $3.79 | $2.20 |
| Resistance Level | $4.19 | $2.61 |
| Average True Range (ATR) | 0.18 | 0.15 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 11.76 | 20.00 |
Ferroglobe PLC provides silicon-based alloys and specialty metals. It produces silicon metal and silicon and manganese-based alloy, serving customers in the specialty chemical, aluminum, solar, steel, and ductile iron foundry industries. The company's operating segments include Canada - Silicon Metals, Canada - Silicon Alloys, U.S. - Silicon Metals, U.S. - Silicon Alloys, Europe - Manganese Alloys, Europe - Silicon Metals, Europe - Silicon Alloys, South Africa - Silicon Metals, South Africa - Silicon Alloys, and Other segments. The primary raw materials the company uses to produce its electrometallurgy products include its coal and quartz mining operations and its silicon metal and ferroalloy production. The firm generates key revenue from Silicon metal and Manganese-based alloys.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.